Journal List > J Korean Surg Soc > v.78(3) > 1011086

TOOLS
Joo, Kim, Choi, Song, Lee, Kim, Kim, Lee, Lee, and Hong: Cyclooxygenase (COX)-1, Cyclooxygenase (COX)-2 and E-cadherin Expression in Colorectal Cancer Patients with Hepatic Metastasis
Original Article
Journal of the Korean Surgical Society

Journal of the Korean Surgical Society 2010; 78(3): 177-183.

Published online: 31 March 2010

DOI: https://doi.org/10.4174/jkss.2010.78.3.177

Cyclooxygenase (COX)-1, Cyclooxygenase (COX)-2 and E-cadherin Expression in Colorectal Cancer Patients with Hepatic Metastasis

Sun Hyung Joo, M.D., Bum Soo Kim, M.D., Sung Il Choi, M.D., Jeong Yoon Song, M.D., Kil Yeon Lee, M.D., Yun Wha Kim, M.D.1, Gyo Young Kim, M.D.1, Suk Hwan Lee, M.D., Sang Mok Lee, M.D., Sung Wha Hong, M.D.

Department of Surgery, School of Medicine, Kyung Hee University, Seoul, Korea.

1Department of Pathology, School of Medicine, Kyung Hee University, Seoul, Korea.

Corresponding author (sunhyung@chol.com)

Received 31 October 2009       Accepted 14 December 2009

Copyright © 2010 The Korean Surgical Society

Abstract

Purpose

Recent studies have shown that cyclooxygenase (COX)-2 may be involved in colorectal carcinogenesis. In this study, we evaluate the differences of COX-2 expression in patients with synchronous and metachronous hepatic metastasis of colorectal cancer. In addition, the expression of COX-1 and E-cadherin were also evaluated.

Methods

Paraffin embedded blocks were obtained from 41 patients who underwent surgery for colorectal cancer with hepatic metastasis. Samples from primary colorectal cancer, synchronous and metachronous hepatic lesions were stained by immunohistochemistry for monoclonal antibody against COX-1, COX-2, and E-cadherin.

Results

In colonic COX-1 expression, there was no significant difference in the degree of COX-1 expression between primary colorectal cancer with synchronous hepatic metastasis and that of metachronous hepatic metastasis (P=0.507). In colonic COX-2 and E-cadherin expression, the degree of COX-2 expression was not different between the two groups. But, the patient survival rate in the positive group of COX-1 and COX-2 expression was lower than in the negative group, respectively (P=0.023, P=0.006).

Conclusion

The degree of colonic COX-1 and COX-2 expression has an impact on prognosis in synchronous and metachronous hepatic metastasis. Further large-scale study is necessary to determine the meaning of COX-2 expression in colorectal cancer.

Keywords: Colorectal cancer, COX-1, COX-2, E-cadherin

Figures and Tables

Fig. 1
Immunochemical staining of COX-1, COX-2 and E-cadherin. (A) Moderate cytoplasmic expression of COX-1 in primary colon cancer (×100). (B) Moderate cytoplasmic expression of COX-1 in hepatic metastasis (×100). (C) Strong cytoplasmic expression of COX-2 in primary colon cancer (×100). (D) Strong cytoplasmic expression of COX-2 in hepatic metastasis (×100). (E) Strong membranous expression of E-cadherin in primary colon cancer (×400). (F) Strong membranous expression of E-cadherin in hepatic metastasis (×400).
jkss-78-177-g001
Fig. 2
Overall survival according to the degree of COX-1expression in primary tumor.
jkss-78-177-g002
Fig. 3
Overall survival according to the degree of COX-2expression in primary tumor.
jkss-78-177-g003
Table 1
Demographic findings of patients
jkss-78-177-i001

*RHC = right hemicolectomy; †LHC = left hemicolectomy; ‡AR = anterior resection; §LAR = low anterior resection; ∥APR = abdomonoperineal resection; TAE = transanal excision; **RL = right hepatectomy; ††PS = posterior sectionectomy; ‡‡LL = left hepatectomy; §§LLS = left lateral sectionectomy; ∥∥S1 = caudate lobectomy; ¶¶W = wedge resection; ***CBS = central bisectionectomy.

Table 2
Differences of COX-1, COX-2 and E-cadherin expression in primary tumor
jkss-78-177-i002
Table 3
COX-1, COX-2 and E-Cadherin expression of primary tumor according to differentiation
jkss-78-177-i003

*W/D = well differentiated; †M/D = moderately differentiated; ‡P/D = poorly differentiated.

Table 4
Differences of COX-1, COX-2 and E-cadherin expression in metastatic tumor
jkss-78-177-i004
Table 5
COX-1, COX-2 and E-Cadherin expression of metastatic tumor according to differentiation
jkss-78-177-i005

*W/D = well differentiated; †M/D = moderately differentiated; ‡P/D = poorly differentiated.

References

1. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer. 1969. 23:198–202.
2. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004. 239:818–827.
3. Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg. 1998. 22:268–277.
4. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg. 1987. 11:541–547.
5. Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg. 1987. 205:264–270.
6. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991. 110:13–29.
7. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996. 77:1254–1262.
8. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995. 55:1464–1472.
9. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991. 325:1593–1596.
10. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997. 39:1–20.
11. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum. 2002. 45:98–103.
12. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971. 231:232–235.
13. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991. 266:12866–12872.
14. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992. 89:7384–7388.
15. DuBois RN, Tsujii M, Bishop P, Awad JA, Makita K, Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol. 1994. 266:G822–G827.
16. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997. 57:1276–1280.
17. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994. 107:1183–1188.
18. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995. 55:3785–3789.
19. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995. 83:493–501.
20. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998. 93:705–716.
21. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004. 10:8465–8471.
22. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999. 282:1254–1257.
23. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development. 1988. 102:639–655.
24. Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, Doki Y, et al. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol. 1999. 111:29–37.
25. Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag PM. Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer. 1999. 35:60–65.
26. Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamoto M, et al. Aberrant expression and phosphorylation of beta-catenin in human colorectal cancer. Br J Cancer. 1998. 77:605–613.
27. Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GJ, Lodge JP. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis. 2000. 18:21–27.
TOOLS
Similar articles